IP Group CEO on 2025 highlights, NAV uplift, Pfizer royalties & capital allocation

IP Group PLC (LSE:IPO) CEO Greg Smith talked with Proactive's Stephen Gunnion about the company’s 2025 results, highlighting 13% growth in NAV per share and the strategic developments across its portfolio. The discussion focused on how IP Group’s exposure to Pfizer’s acquisition of Metsera could generate significant long-term royalty income for shareholders. Smith explained that the company licenses the fundamental intellectual property behind an anti-obesity programme to Pfizer following the pharmaceutical giant’s acquisition of Metsera. The exposure has already been recognised with a £130 million asset valuation, equivalent to around 14p per share. The conversation also covered several portfolio milestones during 2025. These included the successful IPO of Hinge Health on the New York Stock Exchange, which generated strong returns for IP Group, delivering approximately 50 times the company’s original investment after exiting its position. Another key development was the sale of Monolith to Nasdaq-listed CoreWeave, bringing additional proceeds and further payments expected in 2026. Smith also discussed funding activity across the portfolio, including Artios Pharma’s $100 million Series D financing and a £100 million raise by autonomous vehicle company Oxa, backed by investors including the National Wealth Fund and Nvidia’s venture arm. Alongside investments, IP Group has continued to return capital to shareholders through share buybacks, while targeting £250 million in exits by the end of 2027. For more insights from company leaders and market updates, visit the Proactive YouTube channel, give this video a like, subscribe, and enable notifications so you never miss future interviews. #IPGroup #IPGroupPLC #GregSmith #LSEIPO #Pfizer #BiotechInvesting #VentureCapital #UKTech #HingeHealth #Oxa #Artios #HealthcareInnovation #GrowthInvesting #StockMarketUK